Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study

Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study

Abstract Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine/tipiracil (TAS-102), but these drugs have limited clinical efficacy. This study aims to evaluate the efficacy and survival outcomes of ty...

Full description

Saved in:
Bibliographic Details
Main Authors: Chenming Liu, Jintao Chen, Yuxing Liu
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Scientific Reports
Subjects:
Tyrosine kinase inhibitor
Rechallenge therapy
Metastatic colorectal cancer
Overall survival
Progression-free survival
Propensity score matching
Online Access:https://doi.org/10.1038/s41598-025-86575-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-86575-x

Similar Items